{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:56:13Z","timestamp":1753890973530,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hypopharyngeal carcinoma, one of the common malignant tumors of the head and neck, is associated with high tumor aggressiveness, early cervical lymph node metastasis, and a poor prognosis. Neoadjuvant immunotherapy has been gradually introduced to treat locally advanced head and neck squamous cell carcinoma (LA-HNSCC), including hypopharyngeal carcinoma. Despite survival benefit advantages, there is no consensus on the treatment mode after neoadjuvant immunotherapy, especially for patients achieving a complete response (CR). It remains uncertain whether surgery, radical radiotherapy, or maintenance with immunotherapy should be chosen for patients achieving CR. Moreover, there are no reports of the successful use of monoimmunotherapy as maintenance therapy in patients who achieve CR with neoadjuvant immunotherapy. Here, we present the case of an older woman diagnosed with locally advanced hypopharyngeal carcinoma with cervical esophageal involvement who presented with dyspnea and swallowing obstruction. After 18 courses of weekly paclitaxel + carboplatin combined with cetuximab (PCC), during which she received pembrolizumab every 3 weeks, the patient\u2019s laryngoscopy and radiologic imaging results revealed that she had achieved CR. She was subsequently maintained with pembrolizumab alone, and no tumor recurrence was observed on multiple examinations during follow-up. No surgery or radiotherapy was performed. From the beginning of treatment to the present (21 months), the patient\u2019s general condition and quality of life improved significantly (Karnofsky performance status [KPS] = 100), and laryngeal function was well preserved. Our results indicate that patients who achieve CR after neoadjuvant immunotherapy may be maintained with immunotherapy (with surgery or radiotherapy as a salvage measure), which can improve disease-free survival in patients with relatively normal laryngeal function. This single-mode treatment may achieve long-term survival in some LA-HNSCC patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1557565","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:28:05Z","timestamp":1749101285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuous remission of single-mode therapy with pembrolizumab plus chemotherapy in locally advanced hypopharyngeal carcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Guoning","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqiao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingna","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.09.025","article-title":"Hypopharyngeal cancer: A state of the art review","volume":"86","author":"Garneau","year":"2018","journal-title":"Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN guidelines\u00ae Insights: head and neck cancers, version 1.2022: featured updates to the NCCN guidelines","volume":"20","author":"Caudell","year":"2022","journal-title":"J Natl Compr Cancer Network"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01721","article-title":"The evolving landscape of PD-1\/PD-L1 pathway in head and neck cancer","author":"Qiao","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01835-2","article-title":"Treating head and neck cancer in the age of immunotherapy: A 2023 update","volume":"83","author":"Bhatia","year":"2023","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00531-9","article-title":"Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment","volume":"23","author":"Ruffin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23162","article-title":"Tumor immune microenvironment in head and neck cancers","volume":"59","author":"Chen","year":"2020","journal-title":"Mol Carcinogenesis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv368","article-title":"Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, \u00b1 Docetaxel for larynx preservation","volume":"108","author":"Janoray","year":"2016","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70279-5","article-title":"Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial","volume":"12","author":"Lorch","year":"2011","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.6309","article-title":"Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer","volume":"32","author":"Cohen","year":"2014","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local\u2013regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2040","article-title":"895P Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial","volume":"34","author":"Wang","year":"2023","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1038\/s41467-024-49121-3","article-title":"Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial","volume":"15","author":"Gong","year":"2024","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1067\/mhn.2002.124934","article-title":"Promoter hypermethylation: an important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma","volume":"126","author":"Liu","year":"2002","journal-title":"Otolaryngology\u2013Head Neck Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2682","article-title":"Expression characteristics of FHIT, p53, BRCA2 and MLH1 in families with a history of oesophageal cancer in a region with a high incidence of oesophageal cancer","volume":"9","author":"Chang","year":"2015","journal-title":"Oncol Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S278054","article-title":"An update on immune checkpoint therapy for the treatment of Lynch syndrome","author":"Therkildsen","year":"2021","journal-title":"Clin Exp gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trecan.2020.01.007","article-title":"TP53 mutations and outcomes in breast cancer: reading beyond the headlines","volume":"6","author":"Shahbandi","year":"2020","journal-title":"Trends Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2011.449","article-title":"TP53 codon 72 polymorphism is associated with pancreatic cancer risk in males, smokers and drinkers","volume":"4","author":"Sonoyama","year":"2011","journal-title":"Mol Med Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/humu.2016.37.issue-9","article-title":"TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum Mutat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23385","article-title":"TP53 mutations in head and neck cancer","volume":"61","author":"Nathan","year":"2022","journal-title":"Mol Carcinogenesis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-023-01905-9","article-title":"Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients","volume":"22","author":"Sacconi","year":"2023","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643282","article-title":"Predictive value of the TP53\/PIK3CA\/ATM mutation classifier for patients with bladder cancer responding to immune checkpoint inhibitor therapy","author":"Pan","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:28:13Z","timestamp":1749101293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1557565"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1557565","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"article-number":"1557565"}}